Alerts will be sent to your verified email
Verify EmailAJANTPHARM
Ajanta Pharma
|
Gland Pharma
|
JB Chem & Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
76.0 . | 372.0 . | 19.0 . |
Number of ANDA's Approved By USFDA
|
55.0 . | 325.0 . | 17.0 . |
Domestic Sales Growth - YoY
|
7.5 % | n/a | 10.1 % |
R&D as a % of Total Sales
|
4.0 % | 4.4 % | 1.35 % |
Financials
|
|||
5 yr Average ROE
|
21.63 % | 12.02 % | 19.49 % |
5yr average Equity Multiplier
|
1.32 | 1.15 | 1.52 |
5yr Average Asset Turnover Ratio
|
0.84 | 0.51 | 0.77 |
5yr Avg Net Profit Margin
|
19.77 % | 20.79 % | 16.71 % |
Price to Book
|
7.91 | 3.57 | 7.7 |
P/E
|
32.23 | 42.36 | 38.6 |
5yr Avg Cash Conversion Cycle
|
-102.34 Days | 69.81 Days | 7.58 Days |
Inventory Days
|
55.16 Days | 118.26 Days | 50.33 Days |
Days Receivable
|
49.8 Days | 99.92 Days | 67.54 Days |
Days Payable
|
195.69 Days | 107.43 Days | 90.39 Days |
5yr Average Interest Coverage Ratio
|
108.5 | 183.05 | 58.81 |
5yr Avg ROCE
|
27.48 % | 16.55 % | 23.05 % |
5yr Avg Operating Profit Margin
|
27.65 % | 29.26 % | 24.73 % |
5 yr average Debt to Equity
|
0.0 | 0.01 | 0.07 |
5yr CAGR Net Profit
|
7.08 % | -6.87 % | 8.05 % |
5yr Average Return on Assets
|
16.51 % | 10.65 % | 12.98 % |
Shareholdings
|
|||
Promoter Holding
|
66.26 % | 51.83 % | 47.73 % |
Share Pledged by Promoters
|
14.12 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-4.22 % | -6.04 % | -6.27 % |
Change in Mutual Fund Holding (3 Yrs)
|
3.84 % | 15.13 % | 1.15 % |
Ajanta Pharma
|
Gland Pharma
|
JB Chem & Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|